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Abstract 
Purpose: The life‑saving role of oxygen therapy in African children with severe  pneumonia is not yet established.
Methods: The open‑label fractional‑factorial COAST trial randomised eligible Ugandan and Kenyan children 
aged > 28 days with severe pneumonia and severe hypoxaemia stratum  (SpO2 < 80%) to high‑flow nasal therapy 
(HFNT) or low‑flow oxygen (LFO: standard care) and hypoxaemia stratum  (SpO2 80–91%) to HFNT or LFO (liberal 
strategies) or permissive hypoxaemia (ratio 1:1:2). Children with cyanotic heart disease, chronic lung disease or > 3 h 
receipt of oxygen were excluded. The primary endpoint was 48 h mortality; secondary endpoints included mortality 
or neurocognitive sequelae at 28 days.
Results: The trial was stopped early after enrolling 1852/4200 children, including 388 in the severe hypoxaemia 
stratum (median 7 months; median  SpO2 75%) randomised to HFNT (n = 194) or LFO (n = 194) and 1454 in the 
hypoxaemia stratum (median 9 months; median  SpO2 88%) randomised to HFNT (n = 363) vs LFO (n = 364) vs per‑
missive hypoxaemia (n = 727). Per‑protocol 15% of patients in the permissive hypoxaemia group received oxygen 
(when  SpO2 < 80%). In the severe hypoxaemia stratum, 48‑h mortality was 9.3% for HFNT vs. 13.4% for LFO groups. In 
the hypoxaemia stratum, 48‑h mortality was 1.1% for HFNT vs. 2.5% LFO and 1.4% for permissive hypoxaemia. In the 
hypoxaemia stratum, adjusted odds ratio for 48‑h mortality in liberal vs permissive comparison was 1.16 (0.49–2.74; 
p = 0.73); HFNT vs LFO comparison was 0.60 (0.33–1.06; p = 0.08). Strata‑specific 28 day mortality rates were, respec‑
tively: 18.6, 23.4 and 3.3, 4.1, 3.9%. Neurocognitive sequelae were rare.
Conclusions: Respiratory support with HFNT showing potential benefit should prompt further trials.
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Introduction
In Africa, severe pneumonia remains the leading cause of 
mortality in children under 5 years old [1], posing a major 
disease burden on health systems. The World Health 
Organization (WHO) recommends presumptive anti-
biotic treatment and oxygen for those with clinicallyde-
fined severe pneumonia and/or hypoxaemia (peripheral 
oxygen saturation  (SpO2) < 90%) [2]. However, the evi-
dence under-pinning the use of oxygen therapy is weak 
[3] and it is generally poorly targeted using non-specific 
clinical signs [4] since many paediatric services lack pulse 
oximeters [5, 6]. In-hospital mortality among pneumonia 
cases is high (9–16%) with hypoxemic children at fivefold 
greater risk of death [6, 7]. WHO recommends research 
on the targeted use of oxygen therapy together with sim-
ple, non-invasive methods of respiratory support as cost-
effective strategies for improving outcome [3], but these 
have not yet been tested in adequately powered ran-
domised controlled trials [8, 9].
A key challenge for the trial design is the significant 
gap between supply and demand for oxygen in resource-
limited African hospitals. Expense and logistic challenges 
mean that many lack sustainable provision of bottled oxy-
gen [10], as highlighted in a survey of 231 health facilities 
(12 African countries) showing only 43% had an uninter-
rupted source of oxygen, 24% had a functioning oxygen 
concentrator (the WHO-preferred source of oxygen [2]) 
and an only 81 (35%) had uninterrupted electricity sup-
ply (necessary for oxygen concentrators) [11]. Thus, in 
many hospitals children with severe pneumonia receive 
little or no oxygen, whether this contributes to the poor 
outcomes is unknown.
The Children’s Oxygen Administration Strategies Trial 
(COAST) simultaneously addressed two hypotheses. 
First, whether liberal oxygenation strategies in children 
with  SpO2 ≥ 80–91% will decrease mortality (at 48 h and 
up to 28 days) compared with a permissive hypoxia strat-
egy. Second, whether respiratory support with high-flow 
nasal therapy  (OptiFlow™) decreases mortality (at 48  h 
and up to 28 days) compared with low-flow oxygen deliv-
ery (standard care) [12].
Methods
COAST was a two-stratum multicentre, open, fractional-
factorial RCT (see statistical methods, Supplemental 
Appendix) conducted in four Ugandan and two Kenyan 
hospitals. Children aged 28  days to 12  years, hospital-
ised with a history of respiratory illness and any one of 
the 2013 WHO clinical definitions of severe pneumonia 
[13] plus hypoxaemia  (SpO2 < 92%) were enrolled into 
either the severe hypoxaemia stratum  (SpO2 < 80%) or 
the hypoxaemia stratum  (SpO2 80–91%). Children with 
previous diagnosed but uncorrected cyanotic heart dis-
ease, chronic lung disease (excluding asthma), children 
given oxygen given at another health facility (or > 3 h at 
the current hospital) or previous COAST enrolment 
were excluded. In the severe hypoxaemia stratum, eligible 
children were randomised (ratio 1:1) to high-flow nasal 
therapy (HFNT) via  OptiFlow™ or low-flow oxygen deliv-
ery (LFO: standard practice). In the hypoxaemia stratum, 
eligible children were randomised (ratio 1:1:2) to HFNT 
via  OptiFlow™, LFO delivery (standard practice) or per-
missive hypoxaemia since pre-existing data indicated no 
differences in mortality across the  SpO2 range 80–89% 
[12, 14] (see Supplemental Appendix and Trial Protocol).
Screening and randomisation
Children hospitalised with suspected severe pneumonia 
were clinically assessed for eligibility including oxygen 
saturation measurement (BITMOS sat 801 +), which 
are capable of measuring oxygen saturations accurately 
during motion and low peripheral perfusion. Children 
eligible for the hypoxaemia stratum required two  SpO2 
readings of 80–91% 5  min apart. Where prior writ-
ten consent from parents/legal guardians could not be 
obtained, ethics committees approved verbal assent with 
delayed written informed consent as soon as practicable 
[15]. Otherwise informed written consent was obtained 
from parents or guardians before randomization. The 
trial statistician in London generated and kept the 
sequential randomization list, computer-generated using 
variably sized permuted blocks stratified by trial centre. 
Randomisation occurred using consecutively numbered 
packs containing randomised links to opaque sealed 
envelopes ensuring allocation concealment.
Study procedures
Children were managed on general paediatric wards; 
mechanical ventilation facilities were largely unavailable. 
Training in triage and emergency paediatric life support 
was given throughout the trial to optimize case recogni-
tion, supportive management and protocol adherence. 
Basic infrastructural support for emergency care, patient 
monitors, haemoglobin, glucose and lactate point-of-care 
Take home message 
In Africa, in children hospitalised with severe pneumonia with oxy‑
gen saturations between 80 and 91% who did not receive oxygen, 
mortality assessed at 48 h (1.4%) was comparable to the usual 
method of oxygen delivery (low‑flow oxygen; LFO (2.5%)) and in 
those receiving high‑flow nasal therapy (HFNT, 1.1%). The potential 
impact of HFNT on patient‑centred outcomes and on resources, 
particularly oxygen supplies, should stimulate further exploration 
particularly in children with severe pneumonia managed in low 
resource settings.
tests, blood cultures and chest X-rays were provided by 
the study. A structured clinical case report form was 
completed at admission and on reviews at 1 2, 4, 8, 16, 24, 
36 and 48 h.
Oxygen therapy and respiratory support
HFNT was delivered by  AIRVO™2 device (https:// www. 
fphca re. com/), which contains a humidifier with inte-
grated flow generator that delivers, to spontaneous 
breathing patients, high flow warmed and humidified air/
oxygen blend. HFNT was initiated on  FiO2 of 21% (room 
air) with flow rates increase and oxygen titrated in using 
a structured protocol. Reliable sources of oxygen includ-
ing electricity power-back up for the  AIRVO™2 and 
oxygen concentrators were provided to ensure oxygen 
delivery was uninterrupted [11]. LFO was delivered by 
nasal canulae/prongs and escalated to higher flow rates 
delivered by standard masks. Saturations were checked 
at 15-, 30-, and 60-min post-enrolment and during the 
structured reviews. Per-protocol the permissive hypoxae-
mia arm received LFO if  SpO2 fell below 80%. Children 
unable to tolerate HFNT were switched to LFO. From 
2-h post-enrolment oxygen could be weaned/stopped 
if  SpO2 remained ≥ 92% in room air and restarted if 
 SpO2 dropped to < 92%. At 48  h children on HFNT 
were switched to LFO (extra details in Supplemental 
Methods).
All children received standard treatments including 
intravenous maintenance fluids (2.5–4 mls/kg/hour) 
[16], antibiotics, antimalarials, antipyretics, anticonvul-
sants, and transfusion for haemoglobin < 5 g/dl according 
to national guidelines. At the scheduled follow-up visit, 
children were clinically assessed (including neurode-
velopmental assessment) at 28  day post-randomization. 
Clinicians were trained on the structured ‘Kilifi Devel-
opmental Milestones Assessment which covers three 
broad domains of child functioning: motor, language 
and personal–social development [17]. From previous 
experience [18], neurocognitive changes can be tran-
sient, children who exhibiting neurocognitive sequalae at 
28 days were re-assessed at 90 days. Nurses/doctors were 
unblinded; laboratory tests were assayed blinded.
Endpoints
The primary outcome was mortality at 48-h post-ran-
domization (a timepoint capturing the majority of in-
patient deaths [16]) and deaths to Day 28 [19]. Secondary 
outcomes included day-28 mortality, treatment failure at 
48 h (persistent hypoxaemia:  SpO2 < 92% plus respiratory 
distress), time to hypoxaemia resolution  (SpO2 ≥ 92%), 
duration of respiratory (oxygen/HFNT) support, length 
of initial hospital stay, Day-28 neurocognitive/devel-
opmental sequelae, re-admissions and anthropometric 
status (See Statistical Analysis Plan). Adverse events were 
graded using the Common Toxicity Criteria for Adverse 
Events v4.0 [20]. An Endpoint Review Committee (ERC) 
reviewed all deaths blinded to treatment arm.
Statistical analysis
The sample size was determined using simulations, 
assuming a 1:2 ratio between the respective strata and 
48 h mortality in the LFO arms of 26 and 9% in severely 
hypoxaemia and hypoxaemia strata respectively [12]. 
Overall, 4200 children provided at least 90% power 
to detect a 33% relative risk reduction (RR) for liberal 
(HTNT or LFO) vs permissive hypoxaemia and a 25% RR 
for HFNT vs. LFO. Two (of three) planned interim analy-
ses were reviewed by an independent Data Monitoring 
Committee using Haybittle–Peto criterion (p < 0.001) for 
early stopping for either efficacy or harm.
Patients were analysed according to their randomised 
groups, following a prespecified statistical analysis plan. 
The primary outcome was analysed as a binary outcome 
using multilevel logistic regression including both treat-
ment allocation variables simultaneously (HFNT vs. 
LFO, and liberal (any respiratory support) vs. permissive 
hypoxaemia and adjusted for the stratifying factors of 
baseline  SpO2 (grouped as < 80, 80–84, 85–89, 90–91%) 
and trial site (as a random factor). Adjusted odds ratios 
(aOR) with 95% confidence intervals (CI) were calculated 
to compare any respiratory support/oxygen vs permissive 
hypoxaemia (hypoxaemia stratum only), and HFNT vs. 
LFO (primary effect estimates). Each treatment alloca-
tion variable was tested for significance using a likelihood 
ratio test of the reduced compared to full regression 
model fit. (More details in Supplemental Methods).
Results
The trial was stopped prematurely in by the Trial Steer-
ing Committee on the grounds of feasibility as a result 
of a campaign to terminate the trial in Uganda, which 
deemed permissive hypoxaemia (permissive hypoxae-
mia) unethical (detailed in the Supplemental Methods).
Between 14th Feb 2017 and when enrolment ceased 
(28th Feb 2020) 1842 eligible children were enrolled into 
the COAST trial and included in all analyses (Fig. 1), Of 
388 in the severe hypoxaemia stratum, 194 children were 
randomised to HFNT and 194 to LFO. Of 1454 children 
in the hypoxaemia stratum, 363 to were randomised to 
HFNT, 364 to LFO and 727 to permissive hypoxaemia. 
Baseline characteristics are presented in Table 1 demon-
strating multiple features of severe pneumonia were pre-
sent in all children. In the respective strata median  SpO2 
was 75 (68, 78) and 88 (85, 90); 75 and 65% had radio-
graphically confirmed pneumonia. Additional baseline 
features and working diagnoses reported at 48 h are sum-
marised in Supplemental Tables S2a, b.
Adherence to randomisation
Most oxygen therapy was started within 30  min of 
screening except for three children on HFNT who died 
before this timepoint. Adherence to the randomisation 
strategy was excellent (Table  2). Per protocol LFO was 
started in the permissive hypoxaemia arm in 107/726 
(14.7%) for drops of  SpO2 < 80% and in 2 whose  SpO2 
was > 80%. Three children unable to tolerate HFNT were 
switched to LFO.
Use of oxygen and respiratory support
In the severe hypoxaemia stratum, median duration 
(interquartile range, IQR) on respiratory support by 
HFNT was longer than for LFO 36.6  h (9, 48) versus 
32.1 h (7.4, 47.7). In the hypoxaemia stratum duration of 
support by HFNT and LFO were similar (8.4 (2.8, 26.8) 
and 6.8 (2.5, 25.3) hours respectively (Fig.  2; Tables  2 
and Supplemental T2). In the hypoxaemia stratum only 
198/362 (54.7%) on HFNT had oxygen titrated in. In 
the severe hypoxaemia stratum although the number of 
hours of supplemental air/oxygen blend was similar over 
the 48  h period, the mean (standard deviation) volume 
of oxygen (litres) used was lower in HFNT: 2731L/child 
(2733) than LFO: 3591L/child (4128). In the hypoxaemia 
stratum both the time receiving supplemental air/oxygen 
[9.8 (14.6) versus 15.9 (16.6)] hours and oxygen volume 
received [969L/child (1890) versus 1481L/child (2480)] 
were considerably lower in HFNT than LFO. The per-
missive hypoxaemia strategy had lower hours/volume of 
oxygen therapy than the liberal strategies. Baseline  SpO2 
levels in children requiring oxygen in the permissive 
hypoxaemia arm were similar to those never receiving 
oxygen (Supplemental Figure S1).
Mortality and neurocognitive sequelae
Vital status at 48  h (primary endpoint) was known in 
all children 388 (100%) in the severe hypoxaemia stra-
tum and in 363 (100%), 363 (99.7%) and 724 (99.6%) in 
the hypoxaemia stratum children, respectively. By Day 
28 vital status was known in 194 (100%) and 192 (99%) 
in the severe hypoxaemia stratum and in 362 (99.7%), 
362 (99.7%) and 718 (99.2%) in the hypoxaemia stra-
tum children respectively (Supplemental Figure S2). 
By 48  h in the severe hypoxaemia stratum, 18 (9.3%) 
in HFNT versus 26 (13.4%) in LFO groups had died. 
In the hypoxaemia stratum, 4 (1.1%), 9 (2.5%) and 10 
(1.4%) children in HFNT vs LFO vs permissive hypox-
aemia had died. The aOR for liberal versus permissive 
hypoxaemia was 1.16 (95% CI 0.49, 2.74) p = 0.728 and 
for HTNT versus LFO was 0.60 (0.33, 1.06) p = 0.076 
(Table  3). By 28  days, 36 (18.6%) and 45 (23.4%) chil-
dren in the severe hypoxaemia stratum and 12(3.3%), 
15(4.1%) and 28(3.9%) in the hypoxaemia stratum had 
died [aOR for LFO versus permissive hypoxaemia 
0.92 (0.53, 1.59); aOR for HFNT versus LFO was 0.75 
Fig. 1 Asterisk patients were catagorised as absconded if they self‑discharged from hospital against medical advice and subsequently lost to 
follow‑up before 28 days. Double asterisk neurocognitive status was available at 90 days for all children known to have neurocognitive deficit at day 
28
(0.49, 1.16)]. Most neurocognitive sequelae primarily 
reported at Day 28 in survivors were transient, and all 
had resolved by Day 90. Details on blind ERC review 
of deaths and relationship are given in Table 3. Over-
all, there was one event identified by this process that 
was possibly related to treatment arm; most deaths 
appeared to be attributable to the severity of the 
underlying condition or comorbidity.
Table 1 Characteristics of children at baseline by study stratum
a Missing not valid, not done/recorded
Severe hypoxaemia stratum
(Saturations  SpO2 < 80%)
Hypoxaemia stratum











Median age, months (IQR) 7 (2–21) 7 (2–16) 9 (4–24) 9 (4–22) 10 (4–25)
Male sex n (%) 93 (47.9) 97 (50) 213 (58.7) 214 (58.8) 422 (58)
Median  SpO2 (IQR) 75 (68–78) 75 (66–77) 88 (86–89) 88 (86–09) 88 (86–90)
SpO2 < 70% (severe hypoxaemia stratum) 
or < 85% (hypoxaemia stratum) n (%)
55 (28.4) 60 (30.9) 60 (16.5) 65 (17.9) 98 (13.5)
Median weight, kg (IQR) 6.8 (4.8–10) 6.6 (4.8–9) 8.1 (6.4–11) 7.9 (6.2–10.4) 8.3 (6.5–10.8)
Median MUAC, cm (IQR) 13 (11.4–14.2) 13 (11.5–14.2) 14 (13–15) 13.7 (12.7–14.7) 14 (12.8–15)
Fever (> 37.5 °C) n (%) 105 (54.1) 94 (48.5) 191 (52.6) 188 (51.6) 341 (46.9)
Hypothermia (< 36 °C) 5 (2.6) 13 (6.7) 4 (1.1) 9 (2.5) 20 (2.8)
Respiratory rate (IQR) 65 (56–79) 66.5 (56–79) 61 (52–69) 60 (52–68) 60 (51–67)
Tachypnoea n (%) 178 (91.8) 176 (90.7) 330 (90.9) 331 (90.9) 654/726 (90.1)
Indrawing n/N (%) 186/193 (96.4) 187/193 (96.9) 334 (92) 343 (94.2) 658 (90.5)
Cyanosis n/N (%) 13/192 (6.8) 15 (7.7) 3 (0.8) 3 (0.8) 4 (0.6)
Crepitations n/N (%) 136/192 (70.8) 149 (76.8) 271 (74.7) 267 (73.4) 530/725 (73.1)
Wheeze n/N (%) 42/191(22) 37 (19.1) 91/362 (25.1) 93 (25.5) 182/723 (25.2)
Pneumonia signs on chest X‑ray n/N (%) 128/165 (77.6) 113/155 (72.9) 227/347 (65.4) 217/342 (63.5) 426/695 (66.3)
Severe tachycardia n/N (%) 72 (37.1) 77 (39.7) 90/362 (24.9) 100 (27.5) 179 24.6)
Compensated shock n/N (%) 118/193 (61.1) 121 (62.4) 139 (38.3) 145 (39.8) 287 (39.5)
Severe pallor n/N (%) 31/193 (16.1) 24 (12.4) 36 (9.9) 26 (7.1) 57 (7.8)
Vomiting/diarrhoea n/N (%) 62/193 (32.1) 67 (34.5) 120/362 (33.1) 136 (37.4) 239/726 (32.9)
Dehydrated n/N (%) 11/191 (5.8) 20 (10.3) 11 (3) 15/363 (4.1) 22/725 (3)
Conscious level: responds to
 Pain or voice n/N (%) 33 (17) 24 (12.4) 14 (3.9) 14/363(3.9) 26 (3.6)
 Unresponsive n/N (%) 8 (4.1) 13 (6.7) 2 (0.6) 3/363 (0.8) 3 (0.4)
Severely malnourished n/N (%) 19/193 (9.8) 29 (14.9) 10 (2.8) 24/362 (6.6) 33/726 (4.5)
Sickle cell disease n/N (%) 10 (5.2) 7 (3.6) 26 (7.2) 26 (7.1) 40 (5.5)
Developmental delay n/N (%) 16/193 (8.3) 16 (8.2) 21 (5.8) 17/362 (4.7) 40 (5.5)
Median haemoglobin, g/dl (IQR) 9.6 (7.3–11.1) 10.2 (8.7–11.3) 10.2 (8.8 –11.4) 10.3 (8.9–11.4) 10.4(8.9–11.7)
Severe anaemia (Hb < 5/dl) n/N (%) 24/184 (13) 13/182 (7.1) 33/352 (9.4) 26/348 (7.5) 59/698 (8.5)
White cell count (10 × 3/µL) median (IQR) 13.9 (9.5–20.3) 13.2 (9.4–18.7) 12.5 (9.2–17.3) 11.9 (8.3–16.4) 11.9 (8.3–17.9)
Leucocytosis (WBC > 11) n/N (%) 120/184 (65.2) 117/182 (64.3) 204/351 (58.1) 193/347 (55.6) 388/698 (55.6)
HIVa n (%) 6/188 (3.2) 11/188 (5.9) 4/354 (1.1) 15/356 (4.2) 13/707 (1.8)
Malaria  RDTa n/N (%) 25/187 (13.4) 18/181 (9.9) 49/350 (14) 38/352 (10.8) 98/700 (14)
Malaria slide  positivea n (%) 11/187(5.9) 13/182 (7.1) 26/354 (7.3) 15/354 (4.2) 36/700 (5.1)
Bacteraemia n/N (%) 10/187 (5.3) 7/183 (3.8) 8/354 (2.3) 8/353 (2.3) 19/705 (2.7)
Hypoglycaemia (glucose < 3/mmol/L) n (%) 10/192 (5.2) 9/193 (4.7) 7 (1.9) 5 (1.4) 21/727 (2.9)
Lactate > 5 mmol/L n/N (%) 41/191 (21.5) 38/190 (20) 34/354 (9.6) 21/358 (5.9) 54/715 (7.6)
Antibiotics in illness n/N (%) 112/186 (60.2) 121/192 (63) 205/358 (57.3) 201/358 (56.1) 404/721 (56)
Antimalarial in Illness n/N (%) 41/188 (21.8) 42/190 (22.1) 97/361 (26.9) 85/363 (23.4) 169/726 (23.3)
Other clinical outcomes
Treatment failure to 48  h (defined as  SpO2 < 92% plus 
respiratory distress) was somewhat lower in HFNT ver-
sus LFO aOR 0.75 (0.40, 1.41) and lower for liberal ver-
sus permissive hypoxaemia strategy aOR 0.37 (0.19, 0.71) 
(Table 3; Supplemental Figure S3). Further exploration of 
these treatment failures by severity of hypoxaemia (< 80, 
80–89 and 90–91%) and comorbidities are reported in 
Supplemental Table  S3. Overall, in the severe hypoxae-
mia stratum, 14/33 (42.4%) and 12/33 (36%) treatment 
failures were for saturations of < 80 and 80–89%, respec-
tively. Day-28 hospital readmissions were low (≤ 3%) 
across all groups/strata (Supplemental Table  S4). There 
was no evidence of a difference in mean hospital stay in 
the HFNT versus LFO [difference in means 0.26 (95% 
CI − 0.43, 0.94)] or liberal versus permissive hypoxaemia 
[0.62 (0.02, 1.22)] groups nor differences in anthropomet-
ric status at Day 28 (Table 3).
Discussion
The premature termination of the COAST trial meant 
that it was unable answer the two specific hypoth-
eses it was designed to address. First, whether liberal 
oxygenation therapy for children with hypoxaemia  (SpO2 
80–91%) is superior to permissive hypoxaemia. In this 
stratum, however, the overall 48 h and Day 28 mortality 
was low across all arms including the permissive hypox-
aemia arm. Second, as the trial was stopped prematurely 
there were insufficient data to demonstrate that HFNT 
was superior to LFO, but caution that the interpretation 
may be subject to a Type II error i.e. false negative (no 
benefit of HFNT versus LFO) since it was underpowered 
to uncover true effects, should they exist. However, the 
size of reduction (40%) in 48-h mortality warrants fur-
ther investigation particularly for children with severe 
hypoxaemia  (SpO2 < 80%). Notably, across both strata the 
method of HFNT administration was also relatively oxy-
gen-sparing, using room air/oxygen blends without any 
evidence of harm. In the hypoxaemia stratum in many 
cases HFNT was provided on room air, leading to correc-
tion of hypoxaemia, without any evidence of harm.
Although the trial does not provide definitive data to 
inform treatment guidelines, the knowledge acquired 
from the trial adds a new level of uncertainty to the lib-
eral use of oxygen as a supportive therapy [21]. Equipoise, 
centred on the degree of uncertainty about the relative 
Table 2 Respiratory support and oxygen use per randomised strategy
This table reports hours of treatment (and oxygen usage) for all children randomised to the specific strategies
a Two patients in the severe hypoxaemia stratum and one patient in the hypoxaemia stratum died before they started HFNT, one patient in permissive hypoxaemia 
arm absconded numbers initiated are revised according
b Protocol deviation The hypoxaemia stratum: HFNT: one patient switched to low flow before 48 h; low flow: two patients started on HFNT; permissive hypoxaemia: 
two initiated low-flow oxygen at  SpO2 ≥ 80%
c Interruptions in oxygen treatment strategy: high-flow (both strata): power cuts (n = 2), child unable to tolerate (n = 4), nasal/facial trauma (n = 1) and child on 
nebulisation with > 15 min off  O2 therapy (n = 5). Low-flow (both strata): child unable to tolerate (n = 1), child on nebulisation with > 15 min off  O2 therapy (n = 7), 1 
child not specified




(Saturations 80 to < 92%)
HFNT Low flow HFNT Low-flow Permissive hypoxaemia
Number of participants 194 194 363 364 727
Initiated allocated  treatmenta, n/N (%) 192/194 (99) 194/194 (100) 362/363 (99.7) 362/364 (99.5) 726/727 (99.9)
Protocol  deviationb 0 0 1 2 2
Received oxygen  (FiO2 > 21%) ever, n/N (%) 182/192 (93.8) 194/194 (100) 198/362 (54.7) 364/364 (100) 109/726 (15)
Interruptions with treatment  strategyc, n/N (%) 3/192 (1.6) 2/194 (1) 9/362 (2.5) 7/362 (1.9)
Starting flow rate l/min, median (IQR) 14 (10, 20) 1 (1, 2) 16 (13, 22) 1 (1, 2)
Max flow rate, median (IQR) 14 (10, 20) 2 (1.5, 3) 16 (13, 22) 1.5 (1, 2)
Initiated treatment with  FiO2 > 21%, n/N (%) 49/192 (25.5) 194/194 (100) 3/362 (0.8) 363/364 (99.7%)
In the first 48 h
 Hours of respiratory  supportd, mean (sd) 30.4 (18.6) 28 (18.8) 17 (17.2) 15.9 (16.6) 3.5 (10.6)
 Hours of respiratory  supportd, median (IQR) 36.6 (9, 48) 32.1 (7.4, 47.7) 8.4 (2.8, 26.8) 6.8 (2.5, 25.3) 0 (0, 0)
 Hours receiving additional  oxygend, mean (sd) 28.1 (18) 28 (18.8) 9.8 (14.6) 15.9 (16.6) 3.5 (10.6)
 Hours receiving additional  oxygend, median (IQR) 33.1 (8.3–46.7) 32.1 (7.4, 47.7) 1 (0, 18.7) 6.8 (2.5, 25.3) 0 (0, 0)
 Litres of oxygen  usedd, mean (sd) 2731 (2733) 3591 (4128) 969 (1890) 1481 (2480) 359 (1273)
 Litres of oxygen  usedd, median (IQR) 1983 (502, 3571) 2743 (895, 4884) 113 (0, 1454) 480 (236, 2132) 0 (0, 0)
 Any dose escalation n (%) 174 (89.7) 165 (85.1) 222 (60.2) 178 (48.9) 109 (15)
benefits (or risks) of a clinical intervention, requires a 
clear distinction between pre-existing knowledge (evi-
dence) and opinion or personal preference [22]. In the 
case of severe pneumonia, pre-existing evidence dem-
onstrating clear benefits of oxygen therapy was poor [3]. 
On that basis the trial was both ethically and scientifically 
sound [23]. Substantial uncertainty behoves clinicians to 
conduct RCTs so that in future societies will know which 
treatments are better and ensuring patients will not be 
exposed to inferior or harmful treatments.
Whilst oxygen, as a supportive therapy, has been con-
sidered the standard treatment for pneumonia for a 
large part of the last century, the recognition of potential 
oxygen toxicity is relatively recent [24]. In several areas 
of emergency care and resuscitation, the use of oxygen 
(and other therapies included in guidelines [25]) are now 
being challenged by emerging evidence from clinical tri-
als, including in paediatric populations [26, 27], and in 
systematic reviews [21, 28]. In neonates, medical oxygen 
used during resuscitation increases mortality, myocardial 
injury and renal injury [29].
COAST was designed with cognisance of the signifi-
cant gaps between supply and demand for oxygen in hos-
pitals in developing countries [11]. Sustainable provision 
of bottled oxygen is expensive and logistically challenging 
[30]; therefore, the WHO-preferred source of oxygen is 
oxygen concentrators [2]. Nevertheless, technical reports 
on the operational quality, availability and reliability of 
cylinders and oxygen concentrators indicate that, even 
when available, these are often faulty and unsustainable 
due to high cost [10], or depend upon erratic electricity 
supply [11]. With regard to demand on health services, 
the routine use of pulse oximetry to target oxygen ther-
apy is poorly implemented despite having been recom-
mended by WHO for triage of sick children for over two 
decades [5]. Hence, oxygen therapy is generally targeted 
by non-specific clinical signs that predict hypoxaemia 
poorly [4], thus exposing large numbers of children with-
out hypoxaemia to oxygen therapy, and raising questions 
over safety [28, 31], cost and demand for a constrained 
health resource [32]. Our findings indicating that hypox-
aemia in children with severe pneumonia can be cor-
rected without additional oxygen (including those on 
HFNT using room air alone) is timely given the major 
demand on health services for oxygen therapy as a result 
of the COVID-19 epidemic.
Recognising the resource limitations and costs of oxy-
gen therapy, the protocol incorporated relatively oxygen-
sparing strategies in the investigational groups (HFNT 
and permissive hypoxaemia) and vital sign monitoring 
Fig. 2 Proportion of children in each stratum receiving oxygen/respiratory support by group over 48‑ hours post‑randomisation
Table 3 Primary and secondary endpoints
 ~ Treatment failure defined as  SpO2 < 92% in the presence of respiratory distress at 48 h post-randomisation
a Adjusted for initial  SpO2 level (categorised as < 80, 80–84, 85–89, 90–91%) and centre (as a random effect), using a GLM
b In this comparison liberal strategies include HFNT and LFO (versus permissive hypoxaemia)




(Saturations 80 to  < 92%)
Adjusted odds ratio
(95% CI)a
HFNT Low-flow HFNT Low-flow Permissive 
hypoxaemia






 Death (primary 
outcome) n/N 
(%)
18/194 (9.3) 26/194 (13.4) 4/363 (1.1) 9/363 (2.5) 10/724 (1.4) 0.60 (0.33, 1.06) 
(p = 0.076)**
1.16 (0.49, 2.74) 
(p = 0.728)
 Treatment failure 15/175 (8.6) 18/167 (10.8) 5/359 (1.4) 8/353 (2.3) 33/711 (4.6) 0.75 (0.4, 1.41) 0.37 (0.19, 0.71)
 Treatment failure 
or death
33/193 (17.1) 44/193 (22.8) 9/363 (2.5) 17/362 (4.7) 43/721 (6) 0.64 (0.41, 0.99) 0.55 (0.33, 0.91)
At 28 days
 Death n/N (%) 36/194 (18.6) 45/192 (23.4) 12/362 (3.3) 15/362 (4.1) 28/718 (3.9) 0.75 (0.49, 1.16) 0.92 (0.53, 1.59)
 Hospital read‑
mission
2/158 (1.3) 2/147 (1.4) 7/350 (2) 5/347 (1.4) 21/691 (3) 1.26 (0.46, 3.42) 0.56 (0.27, 1.15)
 Neurocognitive 
sequelae
6/158 (3.8) 8/147 (5.4) 9/350(2.6) 11/346 (3.2) 16/689 (2.3) 0.74 (0.37, 1.48) 1.23 (0.63, 2.4)
 Death or neu‑
rocognitive 
sequelae
42/194 (21.6) 53/192 (27.6) 21/362 (5.8) 26/361 (7.2) 44/717 (6.1) 0.74 (0.51, 1.08) 1.04 (0.67, 1.59)
Adjusted difference in meansa 
(95% CI)
Weight for age 
z score, mean 
(s.d.) [N]
− 0.4 (1.8) [141] − 0.6 (1.8) [136] − 0 (1.7) [307] − 0.2 (1.6) [311] − 0.2 (1.6) [633] 0.05 (− 0.05, 0.16) 0.04 (− 0.05, 0.13)
Mid‑upper arm 
circumference
z score, mean 
(s.d.) [N]
− 0.8 (1.3) [93] − 0.7 (1.4) [94] − 0.1 (1.4) [251] − 0.3 (1.3) [257] − 0.2 (1.3) [528] 0.08 (− 0.11, 0.27) 0.02 (− 0.14, 0.17)
Length of stay 
mean (s.d.) [N]
6.3 (5.6) [194] 6.2 (6.1) [194] 5.3 (10.4) [363] 4.9 (3.7) [364] 4.5 (2.9) [726] 0.26 (− 0.43, 0.94) 0.62 (0.02, 1.22)
Serious adverse event
 At least one 
event no. of 
patients (%)
42/194 (21.6) 48/194 (24.7) 26/363 (7.2) 26/364 (7.1) 52/727 (7.2)
 Number of 
events
80 88 49 51 85
Endpoint Review Committee adjudication fatal events relationship to supplemental oxygenb







Endpoint Review Committee adjudication fatal events relationship to delivery method
 Not reviewed 3 6 2 0 1
 Unlikely/unre‑
lated
36 39 14 15 27
 Possibly related 0 0 0 0 1
to ensure early weaning in both liberal (HFNT and LFO) 
strategies (Supplemental Figure S4). Thus, over 48 h even 
in the most liberal of the strategies (LFO) the median vol-
ume of oxygen in the respective strata (3279 and 1337 L/
child) were substantially lower than in a LFO equivalent 
strategy (5990L over a median of 2.5 days) reported in the 
multicentre study in Nigeria investigating oxygen use in 
children with pneumonia [6].
One key limitation of the COAST trial was its prema-
ture termination. Nevertheless, the COAST trial repre-
sents the largest trial of oxygen therapy ever conducted 
in children and the only multicentre controlled trial. 
Another limitation was that we were unable to confirm 
the pulse oximetry readings with arterial blood gases. We 
chose BITMOS sat 801 + , since it incorporates Masimo 
Signal Extraction  Technology® and was the instrument 
of choice in the large multicentre pneumonia aetiol-
ogy study [19]. The substantially lower mortality in both 
strata of the trial, contrast to the mortality rates of 9–10 
and 26–30%, respectively, reported in previous stud-
ies in African children, on which our power calculation 
was based [4, 6, 7, 33]. Most were conducted prior to the 
introduction of vaccines against the lead bacterial causes 
of paediatric pneumonia (Haemophilus influenzae type 
b and Streptococcus pneumoniae) into national immuni-
zation programs (including Uganda and Kenya) and/or 
the scaling-up of prevention and anti-retroviral medica-
tions for HIV. The resultant change in the aetiologic pro-
file of childhood pneumonia was recently demonstrated 
by a multi-country case-control hypoxaemia studies of 
HIV-negative children with radiologically-confirmed 
pneumonia. Only 56/1749 (3·2%) cases had a positive 
blood culture and viruses accounted for 61% of cases. 
Respiratory syncytial virus, which is associated with low 
mortality [34], was the commonest pathogen [19]. The 
WHO severe pneumonia definition maximizes sensitiv-
ity over specificity, resulting in substantial overlap with 
other medical conditions [4, 35]. Notable in the COAST 
trial was the large proportion of previously undiagnosed 
cardiac conditions particularly in the sub-group with 
treatment failure. Nevertheless, radiologically confirmed 
pneumonia was present in a very large proportion of our 
study population, thus generalisable to children hospital-
ised with acute pneumonia in resource-limited hospitals.
HFNT has been shown in other populations to reduce 
the need for mechanical ventilation [36]. In that vast 
majority of hospitals in Africa access to mechanical ven-
tilation or specialist intensive care is not standard. We, 
therefore, proposed that HFNT was a feasible alternative 
source of respiratory support owing to its relative simplic-
ity in implementation, humidification, low risk of nosoco-
mial infection [37]. In addition, the ability to blend both 
oxygen and room air to deliver positive end-expiratory 
pressure, thus, limiting exposure to high concentrations 
of oxygen (and potential toxicity) and with the prospect 
of reducing costs to health services. Bubble continuous 
positive airway pressure (bCPAP) is an alternative means 
of providing respiratory support. However, a recent trial 
in Malawian children showing worse outcomes in chil-
dren receiving bCPAP than usual care advocates caution 
regarding implementation of bCPAP in a real-world set-
ting without physician oversight [9].
In conclusion, our findings support the need for future 
trials with similar designs, particularly in settings where 
access to oxygen and/or mechanical respiratory sup-
port are restricted. The scale of the mortality reduction 
of HFNT over LFO, particularly in severely hypoxae-
mic children (40%) warrants further investigation. Oxy-
gen-sparing strategies potentially offer cost-effective 
approaches to reducing overall oxygen requirements in 
overburdened health services and adds to the general 
findings in critical care than ‘less is more’ [38].
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